Scarica l'app Stockscreener
395.10
0.80%
-2.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$397.55
Aprire:
$394.22
Volume 24 ore:
773.25K
Relative Volume:
0.71
Capitalizzazione di mercato:
$52.19B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,642.83
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
-8.29%
1M Prestazione:
-12.20%
6M Prestazione:
+28.04%
1 anno Prestazione:
+60.67%
Intervallo 1D:
$390.05
$402.33
Intervallo di 1 settimana:
$387.03
$433.31
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
395.05 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.59 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.50 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance - MSN
Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase - simplywall.st
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG - MarketBeat
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
How Good Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), When It Comes To ROE? - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00 - MarketBeat
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes - TradingView — Track All Markets
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
authID (NASDAQ: AUID) PrivacyKey named 2025 PayTech Awards Best Digital Trust Solution - Stock Titan
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 24%? - Yahoo Finance
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a millionaire maker? - MSN
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Can Alnylam Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
5.96%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):